FiercePharma

Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study

When the FDA awarded Biohaven Pharmaceuticals’ migraine med Nurtec ODT with a second indication last month, the company paraded the drug as the only option to both prevent and treat migraines. Now, ...
Seeking Alpha

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
Business Insider

Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine

INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to ...
Healthline

Aimovig Overview: Uses, Side Effects, and More

Aimovig is a brand-name medication that is prescribed to prevent migraine episodes in adults. It is administered via injection, not for treating symptoms as they occur. Common side effects of Aimovig ...
WREG

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...